UChicago Medicine researchers are helping to lead the way for therapies that use the body's immune system to revolutionize the way we treat cancer.
Architect Anwar Hakim turned to UChicago Medicine for a second opinion on treatment for advanced melanoma. Oncologist and melanoma expert Jason Luke, MD, suggested a Phase 1 clinical trial of a combination immunotherapy based on UChicago Medicine research. The treatment worked quickly and side effects were minimal, allowing Hakim to maintain a full work and travel schedule while receiving the therapy. "Six years ago, we didn’t have much to offer patients with advanced melanoma," Luke said. "Now we are seeing unbelievable responses to immunotherapy."
The University of Chicago Medicine is one of a limited number of U.S. sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the U.S. Food and Drug Administration.